Logo image of SRZN

SURROZEN INC (SRZN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SRZN - US86889P2083 - Common Stock

22.1 USD
+1.63 (+7.96%)
Last: 12/9/2025, 8:00:00 PM
22.1 USD
0 (0%)
After Hours: 12/9/2025, 8:00:00 PM
Fundamental Rating

2

Taking everything into account, SRZN scores 2 out of 10 in our fundamental rating. SRZN was compared to 531 industry peers in the Biotechnology industry. The financial health of SRZN is average, but there are quite some concerns on its profitability. SRZN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SRZN had negative earnings in the past year.
SRZN had a negative operating cash flow in the past year.
In the past 5 years SRZN always reported negative net income.
In the past 5 years SRZN always reported negative operating cash flow.
SRZN Yearly Net Income VS EBIT VS OCF VS FCFSRZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of SRZN (-92.41%) is worse than 73.63% of its industry peers.
Industry RankSector Rank
ROA -92.41%
ROE N/A
ROIC N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRZN Yearly ROA, ROE, ROICSRZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SRZN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRZN Yearly Profit, Operating, Gross MarginsSRZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

4

2. Health

2.1 Basic Checks

SRZN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRZN has more shares outstanding
The number of shares outstanding for SRZN has been reduced compared to 5 years ago.
SRZN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SRZN Yearly Shares OutstandingSRZN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SRZN Yearly Total Debt VS Total AssetsSRZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.51, we must say that SRZN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.51, SRZN is not doing good in the industry: 61.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.51
ROIC/WACCN/A
WACC8.81%
SRZN Yearly LT Debt VS Equity VS FCFSRZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 13.15 indicates that SRZN has no problem at all paying its short term obligations.
SRZN has a better Current ratio (13.15) than 88.70% of its industry peers.
SRZN has a Quick Ratio of 13.15. This indicates that SRZN is financially healthy and has no problem in meeting its short term obligations.
SRZN's Quick ratio of 13.15 is amongst the best of the industry. SRZN outperforms 88.70% of its industry peers.
Industry RankSector Rank
Current Ratio 13.15
Quick Ratio 13.15
SRZN Yearly Current Assets VS Current LiabilitesSRZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

SRZN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -110.16%.
SRZN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.96%.
EPS 1Y (TTM)-110.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
Revenue 1Y (TTM)-63.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90.17%

3.2 Future

Based on estimates for the next years, SRZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.05% on average per year.
SRZN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y21.3%
EPS Next 2Y31.09%
EPS Next 3Y20.41%
EPS Next 5Y10.05%
Revenue Next Year-31.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

SRZN Yearly Revenue VS EstimatesSRZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2030 2031 2032 10M 20M 30M 40M
SRZN Yearly EPS VS EstimatesSRZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRZN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRZN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRZN Price Earnings VS Forward Price EarningsSRZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SRZN Per share dataSRZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

SRZN's earnings are expected to grow with 20.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y20.41%

More info and screens

0

5. Dividend

5.1 Amount

SRZN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURROZEN INC

NASDAQ:SRZN (12/9/2025, 8:00:00 PM)

After market: 22.1 0 (0%)

22.1

+1.63 (+7.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners83.91%
Inst Owner Change5.2%
Ins Owners0.52%
Ins Owner Change0.21%
Market Cap189.40M
Revenue(TTM)3.60M
Net Income(TTM)-86.91M
Analysts85
Price Target37.74 (70.77%)
Short Float %1.56%
Short Ratio2.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-148.45%
Min EPS beat(2)-622.12%
Max EPS beat(2)325.23%
EPS beat(4)1
Avg EPS beat(4)-292.69%
Min EPS beat(4)-622.12%
Max EPS beat(4)325.23%
EPS beat(8)4
Avg EPS beat(8)-135.54%
EPS beat(12)6
Avg EPS beat(12)-83.79%
EPS beat(16)9
Avg EPS beat(16)-59.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-6.91%
EPS NQ rev (3m)-6.91%
EPS NY rev (1m)-243.6%
EPS NY rev (3m)-92.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)14.79%
Revenue NY rev (3m)584.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.55
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.34
EYN/A
EPS(NY)-4.31
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.42
BVpS-2.74
TBVpS-2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -92.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.27%
ROA(5y)-71.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.44%
Cap/Sales 2.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.15
Quick Ratio 13.15
Altman-Z -4.51
F-Score3
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)19.96%
Cap/Depr(5y)33.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-110.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1800%
EPS Next Y21.3%
EPS Next 2Y31.09%
EPS Next 3Y20.41%
EPS Next 5Y10.05%
Revenue 1Y (TTM)-63.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-90.17%
Revenue Next Year-31.51%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-42.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-73.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.68%
OCF growth 3YN/A
OCF growth 5YN/A

SURROZEN INC / SRZN FAQ

What is the ChartMill fundamental rating of SURROZEN INC (SRZN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SRZN.


What is the valuation status for SRZN stock?

ChartMill assigns a valuation rating of 1 / 10 to SURROZEN INC (SRZN). This can be considered as Overvalued.


Can you provide the profitability details for SURROZEN INC?

SURROZEN INC (SRZN) has a profitability rating of 0 / 10.


Can you provide the financial health for SRZN stock?

The financial health rating of SURROZEN INC (SRZN) is 4 / 10.


What is the earnings growth outlook for SURROZEN INC?

The Earnings per Share (EPS) of SURROZEN INC (SRZN) is expected to grow by 21.3% in the next year.